A drug that can be taken orally reduces the number of attacks people with multiple sclerosis have, according to new research. After six months, those taking FTY720 had more than 50 percent fewer relapses, or attacks, than those who took the placebo.
A drug that can be taken orally reduces the number of attacks people with multiple sclerosis have, according to new research. After six months, those taking FTY720 had more than 50 percent fewer relapses, or attacks, than those who took the placebo.